Last update 16 May 2026

iCAR-ILC-N101

Overview

Basic Info

Drug Type
CAR-NK, Induced pluripotent stem cells (iPSC)
Synonyms
HLA‐homozygous‐iPSC‐derived anti-GPC3 CAR‐expressing NK/ILC, human leukocyte antigen‐homozygous‐induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells
Target
GPC3
Action
inhibitors
Mechanism
GPC3 inhibitors(Glypican-3 inhibitors)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseUrogenital Diseases
Active Indication-
Inactive Indication
Ovarian CancerOvarian clear cell carcinoma
Originator Organization
Thyas Co., Ltd.Thyas Co., Ltd.
Center for iPS Cell Research & ApplicationCenter for iPS Cell Research & Application
Active Organization-
Inactive Organization
Center for iPS Cell Research & ApplicationCenter for iPS Cell Research & ApplicationNational Cancer Center Hospital EastThyas Co., Ltd.Thyas Co., Ltd.
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with iCAR-ILC-N101
JPRN-jRCT2033200431
/ RecruitingPhase 1IIT
A phase 1 clinical trial of intraperitoneal administration of GPC3-CAR expressing iPS cell-derived innate lymphoid/natural killer cells for patients with GPC3 positive advanced ovarian clear cell carcinoma with peritoneal dissemination
100 Clinical Results associated with iCAR-ILC-N101
Login to view more data
100 Translational Medicine associated with iCAR-ILC-N101
Login to view more data
100 Patents (Medical) associated with iCAR-ILC-N101
Login to view more data
100 Deals associated with iCAR-ILC-N101
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian clear cell carcinomaPhase 1
Japan
National Cancer Center Hospital East
10 May 2021
Ovarian clear cell carcinomaPhase 1
Japan
Center for iPS Cell Research & ApplicationCenter for iPS Cell Research & Application
10 May 2021
Ovarian CancerPreclinical
Japan
Thyas Co., Ltd.Thyas Co., Ltd.
31 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free